Clinical trials in pediatric ALS: a TRICALS feasibility study
Tessa Kliest(Utrecht University), Martin R. Turner(University of Oxford), Susanne Petri(Medizinische Hochschule Hannover), Delia Chaverri(Hospital Universitario La Paz), Cristina Cereda(University of Milan), Magdalena Kuźma‐Kozakiewicz(Medical University of Warsaw), Philippe Corcia(Centre Hospitalier Universitaire de Tours), M.Á. Rubio(Hospital Del Mar), Blaž Koritnik(Centre National de la Recherche Scientifique), Massimiliano Filosto(Anna Needs Neuroblastoma Answers), Ammar Al‐Chalabi(King's College London), Mamede de Carvalho(Hospital de Egas Moniz), Claude Desnuelle(Centre Hospitalier Universitaire de Nice), C. Oliver Hanemann(University of Plymouth), Kirsten Svenstrup(Frederiksberg Hospital), Lev Brylev(Moscow Research and Clinical Center for Neuropsychiatry), Christopher McDermott(University of Sheffield), V. Brunaud-Danel(Université Lille Nord de France), Ruben P. A. van Eijk(University Medical Center Utrecht), Jessica Mandrioli(University of Modena and Reggio Emilia), Hakan Çetin(Medical University of Vienna), Philippe Couratier(Centre Hospitalier Universitaire de Limoges), Thomas Meyer(University Medical Center Freiburg), Caroline Ingre(Karolinska University Hospital), Mónica Povedano(University Medical Center Utrecht), Trygve Holmøy(OsloMet – Oslo Metropolitan University), Geir Bråthen(Norwegian University of Science and Technology), Fabiola De Marchi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Michael A. van Es(University Medical Center Utrecht), Evy Reviers, Julian Großkreutz(Jena University Hospital), Nilo Riva(HUN-REN Institute of Experimental Medicine), Alberto Albanese(Università Cattolica del Sacro Cuore), Anette Torvin Møller(Aarhus University Hospital), Adriano Chiò(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Alberto García‐Redondo, Peter M. Andersen(Umeå University), Christian Lunetta(Istituti Clinici Scientifici Maugeri), Jesús Esteban‐Pérez(Research Institute Hospital 12 de Octubre), Maria del Mar Amador(Sorbonne Université), Zorica Stević(University of Belgrade), Peter Leigh(Brighton and Sussex Medical School), François Salachas(Sorbonne Université), Gianni Sorarú(University of Padua), William Camu(Hôpital Gui de Chauliac), Thomas Lambert(University Hospitals of North Midlands NHS Trust), Jesús S. Mora(Mott MacDonald (United Kingdom)), Kit C. B. Roes(Radboud University Nijmegen), Stayko Sarafov(Alexandrovska Hospital), Helle Høyer(Telemark Hospital)
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
February 16, 2022
Cited by 12
Related Papers
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk
|Nature Genetics|2019|2.5k
Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)
|Clinical Neurophysiology|2014|2.2k
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
|Nature Genetics|2008|1.5k
Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study
|The Lancet Psychiatry|2020|1.3k